Technical Analysis for CALC - CalciMedica, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 200 DMA | Bullish | 0.00% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Volume Surge | Other | 7.32% | |
| Lower Bollinger Band Walk | Weakness | 7.32% | |
| Stochastic Reached Oversold | Weakness | 7.32% | |
| Wide Bands | Range Expansion | 7.32% | |
| Lower Bollinger Band Touch | Weakness | 7.32% | |
| Oversold Stochastic | Weakness | 7.32% |
| Alert | Time |
|---|---|
| 1.5x Volume Pace | about 9 hours ago |
| Down 5% | about 9 hours ago |
| Down 3% | about 9 hours ago |
| Fell Below Lower Bollinger Band | about 9 hours ago |
| Down 2 % | about 9 hours ago |
Get a Trading Assistant
- Earnings date: 08/08/2024
CalciMedica, Inc. Description
CalciMedica is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. CalciMedica’s proprietary technology targets the inhibition of calcium release-activated calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are currently no approved therapies. CalciMedica’s lead product candidate Auxora, a proprietary, intravenous-formulated CRAC channel inhibitor, has demonstrated positive and consistent clinical results in four completed efficacy clinical trials. Auxora is in development for acute pancreatitis and asparaginase-associated pancreatitis. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Medication Inflammatory Diseases Abdominal Pain Pancreatitis Acute Pancreatitis Asparaginase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.38 |
| 52 Week Low | 1.75 |
| Average Volume | 39,574 |
| 200-Day Moving Average | 4.08 |
| 50-Day Moving Average | 5.22 |
| 20-Day Moving Average | 4.96 |
| 10-Day Moving Average | 4.69 |
| Average True Range | 0.51 |
| RSI (14) | 41.18 |
| ADX | 17.33 |
| +DI | 18.08 |
| -DI | 33.37 |
| Chandelier Exit (Long, 3 ATRs) | 4.45 |
| Chandelier Exit (Short, 3 ATRs) | 4.60 |
| Upper Bollinger Bands | 6.11 |
| Lower Bollinger Band | 3.81 |
| Percent B (%b) | 0.19 |
| BandWidth | 46.31 |
| MACD Line | -0.29 |
| MACD Signal Line | -0.15 |
| MACD Histogram | -0.1367 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.27 | ||||
| Resistance 3 (R3) | 5.20 | 4.80 | 5.10 | ||
| Resistance 2 (R2) | 4.80 | 4.54 | 4.83 | 5.04 | |
| Resistance 1 (R1) | 4.52 | 4.38 | 4.66 | 4.59 | 4.99 |
| Pivot Point | 4.12 | 4.12 | 4.19 | 4.15 | 4.12 |
| Support 1 (S1) | 3.84 | 3.86 | 3.98 | 3.91 | 3.51 |
| Support 2 (S2) | 3.44 | 3.70 | 3.47 | 3.46 | |
| Support 3 (S3) | 3.16 | 3.44 | 3.40 | ||
| Support 4 (S4) | 3.23 |
